AQR Capital Management’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.86M Buy
1,319,469
+505,498
+62% +$2.4M ﹤0.01% 1737
2026
Q2
$3.61M Sell
813,971
-98,371
-11% -$420K ﹤0.01% 2214
2026
Q1
$3.99M Buy
912,342
+168,887
+23% +$797K ﹤0.01% 1893
2025
Q4
$3.75M Sell
743,455
-276,435
-27% -$1.28M ﹤0.01% 1751
2025
Q3
$3.54M Sell
1,019,890
-218,503
-18% -$820K ﹤0.01% 1656
2025
Q2
$4.21M Buy
1,238,393
+585,116
+90% +$1.95M ﹤0.01% 1381
2025
Q1
$2.62M Buy
653,277
+521,135
+394% +$2.7M ﹤0.01% 1467
2024
Q4
$858K Buy
132,142
+52,236
+65% +$311K ﹤0.01% 1969
2024
Q3
$443K Buy
79,906
+19,759
+33% +$112K ﹤0.01% 2229
2024
Q2
$336K Buy
60,147
+40,240
+202% +$242K ﹤0.01% 2220
2024
Q1
$134K Sell
19,907
-36,299
-65% -$287K ﹤0.01% 2310
2023
Q4
$513K Buy
56,206
+17,167
+44% +$108K ﹤0.01% 1874
2023
Q3
$215K Buy
39,039
+13,057
+50% +$105K ﹤0.01% 2119
2023
Q2
$222K Buy
+25,982
New +$233K ﹤0.01% 2057
2022
Q4
– Sell
-31,163
Closed -$459K – 2214
2022
Q3
$459K Buy
+31,163
New +$405K ﹤0.01% 1821

Other funds holding CTKB

AQR Capital Management's CTKB Position: Q3 2026 in Review

AQR Capital Management increased its Cytek Biosciences (CTKB) stake by 62% in Q3 2026, buying an estimated $2.4M and bringing the position to 1,319,469 shares worth $7.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

AQR Capital Management first reported a position in CTKB in Q3 2022 and has held it in 15 quarters since. 152 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • AQR Capital Management held 1,319,469 shares of Cytek Biosciences worth $7.86M as of Q3 2026.
  • AQR Capital Management bought 505,498 Cytek Biosciences shares in Q3 2026, an estimated $2.4M.
  • Cytek Biosciences made up ﹤0.01% of AQR Capital Management's portfolio in Q3 2026, its #1737 holding.
  • AQR Capital Management first reported a position in Cytek Biosciences in Q3 2022 and has held it in 15 quarters since.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.